Sun Pharma’s September quarter sales declined by 12% sequentially and by 44% from a year ago. Graphic: Subrata Jana/MintThe waiting game continues as Sun Pharmaceutical Industries Ltd’s Halol facility in Gujarat is yet to be re-inspected by the US Food and Drug Administration (FDA). Sun Pharma’s sales declined by 12% sequentially and by 44% from a year ago. While Sun Pharma’s profitability may have improved due to the sequential decline in expenses, that may not be sustainable. The September quarter results serve to underscore the importance of getting the Halol facility back in the game.

Source: Mint November 15, 2017 01:52 UTC